"The US Food and Drug Administration (FDA) today approved asfotase alfa (Strensiq, Alexion Pharmaceuticals) as the first-ever therapy for patients who develop hypophosphatasia, a rare metabolic bone disorder, in childhood.
1% (Isosulfan Blue) AQUEOUS SOULTION
The chemical name of Lymphazurin 1% (isosulfan blue) is N-[4- [[4-(diethylamino)phenyl] (2,5-disulfophenyl) methylene]-2,5- cyclohexadien-1-ylidene]-N-ethylethanaminium hydroxide, inner salt, sodium salt. Its structural formula is:
Lymphazurin (isosulfan blue) 1% is a sterile aqueous solution for subcutaneous administration. Phosphate buffer in sterile, pyrogen free water is added in sufficient quantity to yield a final pH of 6.8-7.4. Each ml of solution contains 10 mg Isosulfan blue, 6.6 mg sodium monohydrogen phosphate and 2.7 mg potassium dihydrogen phosphate. The solution contains no preservative. Lymphazurin (isosulfan blue) 1% is a contrast agent for the delineation of lymphatic vessels.
Last reviewed on RxList: 2/13/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Lymphazurin Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.